Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
01/11/2007 16:45
PR Newswire
CALGARY, Canada, November 1 /PRNewswire/ -- Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc.
(TSX:ONC, NASDAQ: ONCY), will present a corporate overview of the Company at
the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on
Tuesday, November 6, 2007 at 3:20 p.m. ET. The event will be held at the New
York Palace Hotel from November 5-7, 2007.
A live audio webcast of the presentation will be available at:
http://www.wsw.com/webcast/rrshq12/oncy/ or on the company's website at
http://www.oncolyticsbiotech.com. It is recommended that listeners log on 15
minutes in advance of the presentation to register and download any necessary
software.
An audio replay will be accessible following the presentation at
http://www.oncolyticsbiotech.com.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics' clinical program includes a variety of Phase I and Phase II human
trials using REOLYSIN(R), its proprietary formulation of the human reovirus,
alone and in combination with radiation or chemotherapy. For further
information about Oncolytics, please visit http://www.oncolyticsbiotech.com
The presentation and webcast times are subject to change. This release
and the presentation related thereto contain forward-looking statements which
involve known and unknown risks, delays, uncertainties and other factors not
under the Company's control and which may cause actual results, performance
or achievements of the Company to be materially different from the results,
performance or expectations implied by these forward-looking statements. Such
risks and uncertainties include, among others, the efficacy of REOLYSIN(R) as
a cancer treatment, the success and timely completion of clinical studies and
trials, uncertainties related to the research and development of
pharmaceuticals and uncertainties related to the regulatory process.
Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks
and uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The
Company does not undertake to update these forward-looking statements.
For Canada: Oncolytics Biotech Inc., Cathy Ward, 210, 1167 Kensington Cr NW, Calgary, Alberta, T2N 1X7, Tel: +1-403-670-7377, Fax: +1-403-283-0858, cathy.ward@oncolytics.ca; For Canada: The Equicom Group, Nick Hurst, 325-300 5th Ave. SW, Calgary, Alberta, T2P 3C4, Tel: +1-403-538-4845, Fax: +1-403-237-6916, nhurst@equicomgroup.com; For United States: The Investor Relations Group, Erika Moran, 11 Stone St, 3rd Floor, New York, NY, 10004, Tel: +1-212-825-3210, Fax: +1-212-825-3229, emoran@investorrelationsgroup.com